All Stories

  1. Affinity- and Format-Dependent Pharmacokinetics of 89Zr-Labeled Albumin-Binding VHH Constructs
  2. RBIO-09. Preclinical evaluation of the synergistic effect of heat shock protein 90 inhibitors with temozolomide and external beam radiotherapy in glioblastoma models
  3. [11C]HSP990 PET as a translational tool to investigate the role of Hsp90 in tumours and support the development of Hsp90 therapeutics
  4. In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy
  5. Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain
  6. Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia
  7. PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease
  8. Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT
  9. In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration
  10. Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging
  11. Indium-111-Labeled Single-Domain Antibody for In Vivo CXCR4 Imaging Using Single-Photon Emission Computed Tomography
  12. Development and evaluation of Hsp90-targeting nanobodies for visualisation of extracellular Hsp90 in tumours using PET imaging
  13. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
  14. Development and evaluation of deuterated [18F]JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain
  15. Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924
  16. Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein
  17. Development and Evaluation of Deuterated [18F]JHU94620 Isotopologues for the Non-invasive Assessment of the Cannabinoid Type 2 Receptor in Brain
  18. HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics
  19. Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethyl...
  20. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a mult...
  21. Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging
  22. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
  23. Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [18F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET
  24. Preclinical Evaluation of Novel PET Probes for Dementia
  25. Radiopharmaceuticals for Cancer Imaging and Therapy
  26. Author Correction: Reverse engineering synthetic antiviral amyloids
  27. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
  28. Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
  29. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging
  30. 18F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
  31. In Vivo Detection of Neurofibrillary Tangles by 18 F-MK-6240 PET/MR in Patients With Ischemic Stroke
  32. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/β-Hydrolase Domain 6 (ABHD6)
  33. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging
  34. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
  35. 18F-AlF-NOTA-Octreotide Outperforms68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
  36. Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
  37. Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET
  38. Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
  39. The PET tracer [ 11 C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease
  40. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals
  41. Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
  42. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
  43. Preclinical Evaluation of [11C]YC-72-AB85 for In Vivo Visualization of Heat Shock Protein 90 in Brain and Cancer with Positron Emission Tomography
  44. Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for In Vivo PET Imaging of Intracellular Targets
  45. Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
  46. Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain
  47. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats
  48. Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
  49. Highlight selection of radiochemistry and radiopharmacy developments by editorial board
  50. On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion
  51. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model
  52. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)
  53. Photo isomerization of cis‐cyclooctene to trans‐cyclooctene: Integration of a micro‐flow reactor and separation by specific adsorption
  54. Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain
  55. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
  56. Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects
  57. Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution
  58. Reverse engineering synthetic antiviral amyloids
  59. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
  60. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour
  61. Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging
  62. Translation of HDAC6 PET Imaging Using [18F]EKZ-001–cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates
  63. Development and Evaluation of Interleukin-2–Derived Radiotracers for PET Imaging of T Cells in Mice
  64. Correction to Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
  65. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper
  66. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation
  67. Automated GMP compliant production of [18F]AlF-NOTA-octreotide
  68. Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI
  69. Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
  70. Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging
  71. The Changing Landscape of Early Medicines Development: Be Prepared
  72. Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced α-synucleinopathy
  73. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study
  74. Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients
  75. Design and Challenges of Radiopharmaceuticals
  76. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
  77. Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson’s Disease
  78. Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma
  79. In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration
  80. [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers
  81. Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles
  82. Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
  83. Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET
  84. Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain
  85. 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446
  86. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method
  87. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
  88. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers
  89. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI‐microangiography‐histopathology in rats
  90. Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants
  91. Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
  92. Effects of alcohol exposure on the glutamatergic system: a combined longitudinal 18 F-FPEB and 1 H-MRS study in rats
  93. Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers
  94. Glutamatergic Biomarkers for Cocaine Addiction: A Longitudinal Study Using MR Spectroscopy and mGluR5 PET in Self-Administering Rats
  95. Lower Limbic Metabotropic Glutamate Receptor 5 Availability in Alcohol Dependence
  96. Pretargeted PET Imaging Using a Bioorthogonal 18F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model
  97. Position statement on radiopharmaceutical production for clinical trials
  98. Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study
  99. Synthesis and preclinical evaluation of [ 11 C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL)
  100. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P
  101. Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration
  102. Synthesis, Enzyme Assays and Molecular Docking Studies of Fluorina ted Bioisosteres of Santacruzamate A as Potential HDAC Tracers
  103. Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease
  104. cGMP production of the radiopharmaceutical [18F]MK-6240 for PET imaging of human neurofibrillary tangles
  105. Preclinical Evaluation of18F-JNJ64349311, a Novel PET Tracer for Tau Imaging
  106. Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging
  107. Cholinergic depletion and basal forebrain volume in primary progressive aphasia
  108. Micro-flow photosynthesis of new dienophiles for inverse-electron-demand Diels–Alder reactions. Potential applications for pretargeted in vivo PET imaging
  109. Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)
  110. Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO2: Opportunities for 11C Radiochemistry
  111. The effect of isoflurane on 18F-FDG uptake in the rat brain: a fully conscious dynamic PET study using motion compensation
  112. De novo design of a biologically active amyloid
  113. [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP
  114. Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3
  115. Guidelines to PET measurements of the target occupancy in the brain for drug development
  116. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
  117. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2
  118. Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: An 18F-FPEB PET Study
  119. Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates
  120. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
  121. Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission
  122. New Chelators for Low Temperature Al18F-Labeling of Biomolecules
  123. Kinetic modeling and long-term test-retest reproducibility of the mGluR5 PET tracer18F-FPEB in human brain
  124. Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807
  125. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide
  126. The effect of anaesthesia on18F-FDG uptake in the rat brain: A fully conscious dynamic study using motion correction
  127. Preclinical Evaluation and Quantification of 18F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5
  128. Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F]DPA-714 PET
  129. Retention of [18F]fluoride on reversed phase HPLC columns
  130. PET Imaging of Macrophage Mannose Receptor–Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments
  131. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice
  132. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors
  133. Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia: A [18F]MK-9470 PET Study
  134. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice
  135. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans
  136. Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A
  137. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
  138. PET Radioligands for In Vivo Visualization of Neuroinflammation
  139. Changes in Cerebral CB1Receptor Availability after Acute and Chronic Alcohol Abuse and Monitored Abstinence
  140. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease
  141. Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5)
  142. PET imaging shows loss of striatal PDE10A in patients with Huntington disease
  143. Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers
  144. Brain Imaging of Cannabinoid Receptors
  145. 11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists
  146. Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A
  147. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
  148. Lack of endogenous opioid release during sustained visceral pain: A [11C]carfentanil PET study
  149. Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa
  150. In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
  151. 18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study
  152. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis
  153. Quantification of 18F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test–Retest Study in Human Brain
  154. Synthesis of [18F]RGD-K5 by catalyzed [3+2] cycloaddition for imaging integrin αvβ3 expression in vivo
  155. Construction and Evaluation of Quantitative Small-Animal PET Probabilistic Atlases for [18F]FDG and [18F]FECT Functional Mapping of the Mouse Brain
  156. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study
  157. Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis
  158. Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [11C]-NE40 in Healthy Subjects
  159. Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type‐1 receptors
  160. Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human
  161. New Transient Receptor Potential Vanilloid Subfamily Member 1 Positron Emission Tomography Radioligands: Synthesis, Radiolabeling, and Preclinical Evaluation
  162. PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy
  163. 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity
  164. Preclinical evaluation of carbon-11 and fluorine-18 sulfonamide derivatives for in vivo radiolabeling of erythrocytes
  165. Synthesis and biological evaluation of [11C]SB366791: A new PET-radioligand for in vivo imaging of the TRPV1 receptor
  166. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging
  167. Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET
  168. Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging
  169. Optimized In Vivo Detection of Dopamine Release Using 18F-Fallypride PET
  170. Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model
  171. Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?
  172. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging
  173. Preclinical evaluation and quantification of [18F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain
  174. Noninvasive Molecular Imaging of Neuroinflammation
  175. Recent Advances in Positron Emission Tomography (PET) Radiotracers for Imaging Phosphodiesterases
  176. Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy
  177. Measuring extrastriatal dopamine release during a reward learning task